In general, activated AKT promotes cancer development via phosphorylation and inhibition of the three key downstream effectors, GSK3 (Cross et al., 1995), TSC2 (Menon et al., 2014), and FOXO (Brunet et al., 1999). This evidence concerns the gene TSC2 and cancer.